Predicting optimal scheduling of drug combinations in lung cancer xenografts using a population PK/PD model

Authors: Traynard P
Conference: SLP MIDD+
Keywords: bevacizumab, chemotherapy, cytotoxicity, non-small cell lung cancer, Pre-Clinical, SLP2021MIDD
Software: Monolix®, Simulx®
Division: Lixoft

Introduction

Context:

  • Bevacizumab-pemetrexed/cisplatin is a first-line therapeutic for advanced nonsquamous non-small cell lung cancer.
  • Bevacizumab potentiates pemetrexed/cisplatin (chemotherapy) cytotoxicity by inducing transient tumor vasculature normalization.
  • The increase in neoplasm vascular quality because of bevacizumab typically occurs within a period of a few days after administration.

Goal of the study:

  • Estimate the optimal gap between administration of bevacizumab and chemotherapy to reach full cytotoxicity activation

By Pauline Traynard

Download Slides

Presented at SLP MIDD+ Virtual Conference March 3-4, 2021